Drug Trial Radar · NCT07484204
Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Sep 14, 2026
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Anxo Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.
Conditions
- Schizophrenia
Interventions
AX251 LAI 45 mgDrug
Cariprazine 45 mg
AX251 LAI 90 mgDrug
Cariprazine 90 mg
AX251 LAI 135 mgDrug
Cariprazine 135 mg
AX251 LAI 180 mgDrug
Cariprazine 180 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic ParameterTime frame: Day 1 pre-dose and 1, 2, 3, 4, 8, 12, and 24 hours post-dose. Days 3, 5, 7, 14, 21, 28, 42, 56, and 70
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
DHS Multispeciality Hospital
Ahmedabad, India · Recruiting
Health Hospital
Ahmedabad, India · Recruiting
Divine Multispeciality Hospital
Gandhinagar, India · Recruiting
Ratandeep Multispeciality Hospital
Nagar, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.